A Study of EPEG in Beta Thalassemia Patients
NCT02950857 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2018-05-25
Summary
An open-label study in which 6 patients will receive once-weekly subcutaneous injections of EPEG for 4 weeks. Final visit will occur 60 days after study entry
Conditions
Interventions
- DRUG
-
EPEG
(Pegylated erythropoeitin)
Sponsors & Collaborators
-
Prolong Pharmaceuticals
lead INDUSTRY
Principal Investigators
-
Rosa Real, MD · Prolong Pharmaceuticals
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-06-28
- Primary Completion
- 2017-09-27
- Completion
- 2017-09-27
Countries
- Thailand
Study Locations
More Related Trials
-
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
NCT02633943 ·Status: ACTIVE_NOT_RECRUITING
-
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
NCT05864170 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
NCT02906202 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
NCT06308159 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.
NCT05567458 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
NCT05745532 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
NCT02151526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
NCT03207009 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia
NCT06164821 ·Status: RECRUITING ·Phase: NA
-
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
NCT01745120 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
NCT01571635 ·Status: TERMINATED ·Phase: PHASE2
-
Gene Therapy for Transfusion Dependent Beta-thalassemia
NCT02453477 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
NCT05462548 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
NCT05664737 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT04770779 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
NCT02957643 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
NCT06655662 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants
NCT05015920 ·Status: COMPLETED ·Phase: NA
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
NCT02604433 ·Status: COMPLETED ·Phase: PHASE3
-
Iron Therapy in Erythropoietic Protoporphyria
NCT05572125 ·Status: COMPLETED
-
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
NCT01749540 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)
NCT03275051 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA